JP2000510124A5 - - Google Patents

Download PDF

Info

Publication number
JP2000510124A5
JP2000510124A5 JP1997540211A JP54021197A JP2000510124A5 JP 2000510124 A5 JP2000510124 A5 JP 2000510124A5 JP 1997540211 A JP1997540211 A JP 1997540211A JP 54021197 A JP54021197 A JP 54021197A JP 2000510124 A5 JP2000510124 A5 JP 2000510124A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997540211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000510124A (ja
JP4766722B2 (ja
Filing date
Publication date
Priority claimed from US08/643,321 external-priority patent/US6498142B1/en
Application filed filed Critical
Publication of JP2000510124A publication Critical patent/JP2000510124A/ja
Publication of JP2000510124A5 publication Critical patent/JP2000510124A5/ja
Application granted granted Critical
Publication of JP4766722B2 publication Critical patent/JP4766722B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP54021197A 1996-05-06 1997-05-06 慢性腎不全の形態形成因子処置 Expired - Fee Related JP4766722B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
US08/643,321 1996-05-06
PCT/US1997/007816 WO1997041881A1 (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009126963A Division JP5247593B2 (ja) 1996-05-06 2009-05-26 慢性腎不全の形態形成因子処置

Publications (3)

Publication Number Publication Date
JP2000510124A JP2000510124A (ja) 2000-08-08
JP2000510124A5 true JP2000510124A5 (enExample) 2005-01-13
JP4766722B2 JP4766722B2 (ja) 2011-09-07

Family

ID=24580305

Family Applications (4)

Application Number Title Priority Date Filing Date
JP09540150A Pending JP2000510835A (ja) 1996-05-06 1997-05-06 慢性腎不全の治療
JP54021197A Expired - Fee Related JP4766722B2 (ja) 1996-05-06 1997-05-06 慢性腎不全の形態形成因子処置
JP2009126963A Expired - Fee Related JP5247593B2 (ja) 1996-05-06 2009-05-26 慢性腎不全の形態形成因子処置
JP2012179876A Withdrawn JP2012229268A (ja) 1996-05-06 2012-08-14 慢性腎不全の形態形成因子処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP09540150A Pending JP2000510835A (ja) 1996-05-06 1997-05-06 慢性腎不全の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009126963A Expired - Fee Related JP5247593B2 (ja) 1996-05-06 2009-05-26 慢性腎不全の形態形成因子処置
JP2012179876A Withdrawn JP2012229268A (ja) 1996-05-06 2012-08-14 慢性腎不全の形態形成因子処置

Country Status (11)

Country Link
US (5) US6498142B1 (enExample)
EP (2) EP0910400B1 (enExample)
JP (4) JP2000510835A (enExample)
AT (2) ATE277629T1 (enExample)
AU (2) AU2832297A (enExample)
CA (2) CA2254953C (enExample)
DE (2) DE69723845T2 (enExample)
DK (2) DK0910400T3 (enExample)
ES (2) ES2230604T3 (enExample)
PT (2) PT914146E (enExample)
WO (2) WO1997041881A1 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998050060A1 (en) * 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
EP0896825B1 (en) 1997-08-14 2002-07-17 Sulzer Innotec Ag Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
EP1037910A2 (en) * 1997-12-04 2000-09-27 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
AU765832B2 (en) * 1998-07-28 2003-10-02 Johns Hopkins University School Of Medicine, The Growth differentiation factor-11
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
JP4975922B2 (ja) * 1999-09-14 2012-07-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
EP1578360A4 (en) * 2002-08-28 2009-10-21 Curis Inc JOINT ADMINISTRATION OF MORPHOGENES AND ANGIOTENSIN ENZYME CONVERTING INHIBITORS FOR THE TREATMENT OF CHRONIC RENAL FAILURE
EP2441474B1 (en) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
CA2557999C (en) 2004-03-30 2013-11-12 Ilypsa, Inc. Methods and compositions for treatment of ion imbalances
WO2005097825A2 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
US20100150885A1 (en) * 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
CA2629522A1 (en) * 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20070196810A1 (en) * 2006-01-24 2007-08-23 Northfield Laboratories Inc. Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
EP2035835B1 (en) 2006-05-30 2011-12-28 Antibodyshop A/S Methods for rapid assessment of severity of a trauma
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
EP2574625B1 (en) * 2006-07-21 2015-02-25 HuBit genomix, Inc. Remedy for renal disease
US20080255181A1 (en) * 2006-12-15 2008-10-16 University Of Heidelberg Methods for treating podocyte-related disorders
WO2008134297A2 (en) * 2007-04-24 2008-11-06 Johnson & Johnson Regenerative Therapeutics, Llc Engineered renal tissue
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
AU2009244308A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009157165A1 (ja) * 2008-06-24 2009-12-30 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
BRPI0917711A2 (pt) * 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
WO2010025434A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN106370857A (zh) 2008-10-21 2017-02-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN104076152B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
JP5752600B2 (ja) 2008-11-10 2015-07-22 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
CN103439510B (zh) * 2008-11-22 2016-09-14 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
AU2010210535B2 (en) * 2009-02-06 2015-12-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20100204124A1 (en) * 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
WO2010093925A2 (en) * 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
AU2010223268B2 (en) 2009-03-12 2015-04-23 Haase Investments Gmbh Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US8871459B2 (en) 2009-08-07 2014-10-28 Astute Medical, Inc. Method for evaluating renal status by determining beta-2-glycoprotein 1
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
NZ599773A (en) 2009-11-07 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CA2785038A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
CA2788826C (en) 2010-02-05 2023-09-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
WO2012023113A2 (en) 2010-08-20 2012-02-23 Wyeth Llc Designer osteogenic proteins
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104822383A (zh) 2012-10-08 2015-08-05 瑞立普萨公司 治疗高血压和高血钾症的钾结合剂
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
CA2929831C (en) * 2013-11-11 2020-04-14 General Electric Company Method for reducing error in rotor speed measurements
EP2944326B1 (en) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN109844526A (zh) 2016-06-06 2019-06-04 机敏医药股份有限公司 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
ES2113857T3 (es) 1989-03-28 1998-05-16 Genetics Inst Composiciones osteoinductoras.
DE69132823T2 (de) 1990-05-16 2002-07-18 Genetics Institute, Inc. Knochen- und knorpel-bildung hervorrufende proteine
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
DE69123582T2 (de) * 1990-06-22 1997-05-15 E.I. Du Pont De Nemours & Co., Wilmington, Del. Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
US6194376B1 (en) 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
CA2363965C (en) 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
AU660019B2 (en) 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
DE69233559T2 (de) 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
ATE197611T1 (de) 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
CA2116562C (en) 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
EP0653942B2 (en) 1992-07-31 2007-03-07 Curis, Inc. Morphogen-induced nerve regeneration and repair
ES2118253T3 (es) 1992-07-31 1998-09-16 Creative Biomolecules Inc Composicion dietetica enriquecida con morfogen.
AU678380B2 (en) 1992-07-31 1997-05-29 Stryker Corporation Morphogenic protein soluble complex and composition thereof
EP0661987B1 (en) 1992-09-16 1998-01-14 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
EP0672064A1 (en) 1992-11-03 1995-09-20 Creative Biomolecules, Inc. Op-3-induced morphogenesis
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
WO1994020539A1 (en) 1993-03-04 1994-09-15 Creative Biomolecules, Inc. Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE69723429T3 (de) 1996-03-22 2007-09-20 Curis, Inc., Cambridge Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Similar Documents

Publication Publication Date Title
JP2000506415A5 (enExample)
JP2000514457A5 (enExample)
JP2001502561A5 (enExample)
JP2001502191A5 (enExample)
JP2000514264A5 (enExample)
JP2000517115A5 (enExample)
JP2000517499A5 (enExample)
JP2000509578A5 (enExample)
JP2000510014A5 (enExample)
JP2001505863A5 (enExample)
JP2000516487A5 (enExample)
JP2000513390A5 (enExample)
JP2001503573A5 (enExample)
JP2000511510A5 (enExample)
JP2001503736A5 (enExample)
JP2001503031A5 (enExample)
JP2001525689A5 (enExample)
JP2000516911A5 (enExample)
JP2001503459A5 (enExample)
JP2001504980A5 (enExample)
JP2000510510A5 (enExample)
JP2001503324A5 (enExample)
JP2001501286A5 (enExample)
JP2000516705A5 (enExample)
JP2001504437A5 (enExample)